Skip to main
CRVO

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed is a clinical biotechnology company that is developing a potential treatment for age-related neurologic disorders called Neflamapimod. They have a strong pipeline and have recently secured funding for a pivotal clinical trial for ALS and strengthened their balance sheet through a private placement and equity offering. The completion of their mid-stage trial is expected to yield positive results, and their product revenue is expected to increase in the future.

Bears say

CervoMed is a clinical-stage biotechnology company that is still in the early phases of development and has yet to generate significant revenue. The analysis of neflamapimod's treatment potential in neurodegenerative diseases, including dementia with Lewy bodies and frontotemporal dementia, is promising but still needs to undergo further clinical trials. Despite the potential of their product candidate, CervoMed's financials show low revenue and high operating expenses, making their stock unattractive to investors.

CervoMed Inc (CRVO) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 5 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.